Clinical Trial Update: Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) [Phase 2, Phase 3]

View source ↗

Summary

The document reports the completion status of a Phase 2/3 clinical trial evaluating intravesical valrubicin (AD 32) for carcinoma in situ of the bladder in pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma in Situ of the Bladder

Drugs mentioned

• Valrubicin (valrubicin)

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Carcinoma in Situ, Bladder Cancer | Phase 2, Phase 3 | Status: COMPLETED